aluates Reports

$ 0.0

Automative

Global Pulmonary Embolism Drug Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-0I10272

Global Pulmonary Embolism Drug Market Insights Forecast to 2028

BUY CHAPTERS

Global Pulmonary Embolism Drug Market Research Report 2025

Code: QYRE-Auto-0I10272

Report

January 2025

Pages:75

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Accu-Break Pharmaceuticals, Inc.

Dong-A Socio Holdings Co Ltd

F Hoffmann La Roche Ltd

Genentech Inc

Verseon Corp

Pulmonary Embolism Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Pulmonary Embolism Drug Market

The global market for Pulmonary Embolism Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Pulmonary Embolism Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Embolism Drug.

The Pulmonary Embolism Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pulmonary Embolism Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Pulmonary Embolism Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Pulmonary Embolism Drug Market Report

Report Metric	Details
Report Name	Pulmonary Embolism Drug Market
CAGR	5%
Segment by Type	DS-9231 DS-1040 TRX-1 Others
Segment by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Accu-Break Pharmaceuticals, Inc., Dong-A Socio Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech, Inc., Verseon Corp
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pulmonary Embolism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pulmonary Embolism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Pulmonary Embolism Drug Market report?

Ans: The main players in the Pulmonary Embolism Drug Market are Accu-Break Pharmaceuticals, Inc., Dong-A Socio Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech, Inc., Verseon Corp

What are the Application segmentation covered in the Pulmonary Embolism Drug Market report?

Ans: The Applications covered in the Pulmonary Embolism Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Pulmonary Embolism Drug Market report?

Ans: The Types covered in the Pulmonary Embolism Drug Market report are DS-9231, DS-1040, TRX-1, Others

Recommended Reports

Pulmonary & Respiratory Drugs

Cardiovascular Drug Markets

Diagnostic & Treatment Devices

1 Pulmonary Embolism Drug Market Overview

1.1 Product Definition

1.2 Pulmonary Embolism Drug by Type

1.2.1 Global Pulmonary Embolism Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 DS-9231

1.2.3 DS-1040

1.2.4 TRX-1

1.2.5 Others

1.3 Pulmonary Embolism Drug by Application

1.3.1 Global Pulmonary Embolism Drug Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Pulmonary Embolism Drug Market Size Estimates and Forecasts

1.4.1 Global Pulmonary Embolism Drug Revenue 2020-2031

1.4.2 Global Pulmonary Embolism Drug Sales 2020-2031

1.4.3 Global Pulmonary Embolism Drug Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Pulmonary Embolism Drug Market Competition by Manufacturers

2.1 Global Pulmonary Embolism Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global Pulmonary Embolism Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Pulmonary Embolism Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Pulmonary Embolism Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Pulmonary Embolism Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Pulmonary Embolism Drug, Product Type & Application

2.7 Global Key Manufacturers of Pulmonary Embolism Drug, Date of Enter into This Industry

2.8 Global Pulmonary Embolism Drug Market Competitive Situation and Trends

2.8.1 Global Pulmonary Embolism Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Pulmonary Embolism Drug Players Market Share by Revenue

2.8.3 Global Pulmonary Embolism Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Pulmonary Embolism Drug Market Scenario by Region

3.1 Global Pulmonary Embolism Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Pulmonary Embolism Drug Sales by Region: 2020-2031

3.2.1 Global Pulmonary Embolism Drug Sales by Region: 2020-2025

3.2.2 Global Pulmonary Embolism Drug Sales by Region: 2026-2031

3.3 Global Pulmonary Embolism Drug Revenue by Region: 2020-2031

3.3.1 Global Pulmonary Embolism Drug Revenue by Region: 2020-2025

3.3.2 Global Pulmonary Embolism Drug Revenue by Region: 2026-2031

3.4 North America Pulmonary Embolism Drug Market Facts & Figures by Country

3.4.1 North America Pulmonary Embolism Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Pulmonary Embolism Drug Sales by Country (2020-2031)

3.4.3 North America Pulmonary Embolism Drug Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Pulmonary Embolism Drug Market Facts & Figures by Country

3.5.1 Europe Pulmonary Embolism Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Pulmonary Embolism Drug Sales by Country (2020-2031)

3.5.3 Europe Pulmonary Embolism Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Pulmonary Embolism Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Pulmonary Embolism Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Pulmonary Embolism Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific Pulmonary Embolism Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Pulmonary Embolism Drug Market Facts & Figures by Country

3.7.1 Latin America Pulmonary Embolism Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Pulmonary Embolism Drug Sales by Country (2020-2031)

3.7.3 Latin America Pulmonary Embolism Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Pulmonary Embolism Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Pulmonary Embolism Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Pulmonary Embolism Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa Pulmonary Embolism Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Pulmonary Embolism Drug Sales by Type (2020-2031)

4.1.1 Global Pulmonary Embolism Drug Sales by Type (2020-2025)

4.1.2 Global Pulmonary Embolism Drug Sales by Type (2026-2031)

4.1.3 Global Pulmonary Embolism Drug Sales Market Share by Type (2020-2031)

4.2 Global Pulmonary Embolism Drug Revenue by Type (2020-2031)

4.2.1 Global Pulmonary Embolism Drug Revenue by Type (2020-2025)

4.2.2 Global Pulmonary Embolism Drug Revenue by Type (2026-2031)

4.2.3 Global Pulmonary Embolism Drug Revenue Market Share by Type (2020-2031)

4.3 Global Pulmonary Embolism Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global Pulmonary Embolism Drug Sales by Application (2020-2031)

5.1.1 Global Pulmonary Embolism Drug Sales by Application (2020-2025)

5.1.2 Global Pulmonary Embolism Drug Sales by Application (2026-2031)

5.1.3 Global Pulmonary Embolism Drug Sales Market Share by Application (2020-2031)

5.2 Global Pulmonary Embolism Drug Revenue by Application (2020-2031)

5.2.1 Global Pulmonary Embolism Drug Revenue by Application (2020-2025)

5.2.2 Global Pulmonary Embolism Drug Revenue by Application (2026-2031)

5.2.3 Global Pulmonary Embolism Drug Revenue Market Share by Application (2020-2031)

5.3 Global Pulmonary Embolism Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Accu-Break Pharmaceuticals, Inc.

6.1.1 Accu-Break Pharmaceuticals, Inc. Company Information

6.1.2 Accu-Break Pharmaceuticals, Inc. Description and Business Overview

6.1.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolio

6.1.5 Accu-Break Pharmaceuticals, Inc. Recent Developments/Updates

6.2 Dong-A Socio Holdings Co. Ltd.

6.2.1 Dong-A Socio Holdings Co. Ltd. Company Information

6.2.2 Dong-A Socio Holdings Co. Ltd. Description and Business Overview

6.2.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolio

6.2.5 Dong-A Socio Holdings Co. Ltd. Recent Developments/Updates

6.3 F. Hoffmann-La Roche Ltd.

6.3.1 F. Hoffmann-La Roche Ltd. Company Information

6.3.2 F. Hoffmann-La Roche Ltd. Description and Business Overview

6.3.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolio

6.3.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates

6.4 Genentech, Inc.

6.4.1 Genentech, Inc. Company Information

6.4.2 Genentech, Inc. Description and Business Overview

6.4.3 Genentech, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Genentech, Inc. Pulmonary Embolism Drug Product Portfolio

6.4.5 Genentech, Inc. Recent Developments/Updates

6.5 Verseon Corp

6.5.1 Verseon Corp Company Information

6.5.2 Verseon Corp Description and Business Overview

6.5.3 Verseon Corp Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Verseon Corp Pulmonary Embolism Drug Product Portfolio

6.5.5 Verseon Corp Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Pulmonary Embolism Drug Industry Chain Analysis

7.2 Pulmonary Embolism Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Pulmonary Embolism Drug Production Mode & Process Analysis

7.4 Pulmonary Embolism Drug Sales and Marketing

7.4.1 Pulmonary Embolism Drug Sales Channels

7.4.2 Pulmonary Embolism Drug Distributors

7.5 Pulmonary Embolism Drug Customer Analysis

8 Pulmonary Embolism Drug Market Dynamics

8.1 Pulmonary Embolism Drug Industry Trends

8.2 Pulmonary Embolism Drug Market Drivers

8.3 Pulmonary Embolism Drug Market Challenges

8.4 Pulmonary Embolism Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Accu-Break Pharmaceuticals, Inc.

Dong-A Socio Holdings Co Ltd

F Hoffmann La Roche Ltd

Genentech Inc

Verseon Corp

List of Tables

Table 1. Global Pulmonary Embolism Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Pulmonary Embolism Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Pulmonary Embolism Drug Market Competitive Situation by Manufacturers in 2024

Table 4. Global Pulmonary Embolism Drug Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Pulmonary Embolism Drug Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Pulmonary Embolism Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Pulmonary Embolism Drug Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Pulmonary Embolism Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Pulmonary Embolism Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Pulmonary Embolism Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Pulmonary Embolism Drug, Product Type & Application

Table 12. Global Key Manufacturers of Pulmonary Embolism Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Pulmonary Embolism Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Embolism Drug as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Pulmonary Embolism Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Pulmonary Embolism Drug Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Pulmonary Embolism Drug Sales Market Share by Region (2020-2025)

Table 19. Global Pulmonary Embolism Drug Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Pulmonary Embolism Drug Sales Market Share by Region (2026-2031)

Table 21. Global Pulmonary Embolism Drug Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Pulmonary Embolism Drug Revenue Market Share by Region (2020-2025)

Table 23. Global Pulmonary Embolism Drug Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Pulmonary Embolism Drug Revenue Market Share by Region (2026-2031)

Table 25. North America Pulmonary Embolism Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Pulmonary Embolism Drug Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Pulmonary Embolism Drug Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Pulmonary Embolism Drug Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Pulmonary Embolism Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Pulmonary Embolism Drug Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Pulmonary Embolism Drug Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Pulmonary Embolism Drug Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Pulmonary Embolism Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Pulmonary Embolism Drug Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Pulmonary Embolism Drug Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Pulmonary Embolism Drug Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Pulmonary Embolism Drug Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Pulmonary Embolism Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Pulmonary Embolism Drug Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Pulmonary Embolism Drug Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Pulmonary Embolism Drug Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Pulmonary Embolism Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Pulmonary Embolism Drug Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Pulmonary Embolism Drug Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Pulmonary Embolism Drug Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Pulmonary Embolism Drug Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Pulmonary Embolism Drug Sales (K Pcs) by Type (2020-2025)

Table 51. Global Pulmonary Embolism Drug Sales (K Pcs) by Type (2026-2031)

Table 52. Global Pulmonary Embolism Drug Sales Market Share by Type (2020-2025)

Table 53. Global Pulmonary Embolism Drug Sales Market Share by Type (2026-2031)

Table 54. Global Pulmonary Embolism Drug Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Pulmonary Embolism Drug Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Pulmonary Embolism Drug Revenue Market Share by Type (2020-2025)

Table 57. Global Pulmonary Embolism Drug Revenue Market Share by Type (2026-2031)

Table 58. Global Pulmonary Embolism Drug Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Pulmonary Embolism Drug Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Pulmonary Embolism Drug Sales (K Pcs) by Application (2020-2025)

Table 61. Global Pulmonary Embolism Drug Sales (K Pcs) by Application (2026-2031)

Table 62. Global Pulmonary Embolism Drug Sales Market Share by Application (2020-2025)

Table 63. Global Pulmonary Embolism Drug Sales Market Share by Application (2026-2031)

Table 64. Global Pulmonary Embolism Drug Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Pulmonary Embolism Drug Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Pulmonary Embolism Drug Revenue Market Share by Application (2020-2025)

Table 67. Global Pulmonary Embolism Drug Revenue Market Share by Application (2026-2031)

Table 68. Global Pulmonary Embolism Drug Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Pulmonary Embolism Drug Price (USD/Pcs) by Application (2026-2031)

Table 70. Accu-Break Pharmaceuticals, Inc. Company Information

Table 71. Accu-Break Pharmaceuticals, Inc. Description and Business Overview

Table 72. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product

Table 74. Accu-Break Pharmaceuticals, Inc. Recent Developments/Updates

Table 75. Dong-A Socio Holdings Co. Ltd. Company Information

Table 76. Dong-A Socio Holdings Co. Ltd. Description and Business Overview

Table 77. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product

Table 79. Dong-A Socio Holdings Co. Ltd. Recent Developments/Updates

Table 80. F. Hoffmann-La Roche Ltd. Company Information

Table 81. F. Hoffmann-La Roche Ltd. Description and Business Overview

Table 82. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product

Table 84. F. Hoffmann-La Roche Ltd. Recent Developments/Updates

Table 85. Genentech, Inc. Company Information

Table 86. Genentech, Inc. Description and Business Overview

Table 87. Genentech, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. Genentech, Inc. Pulmonary Embolism Drug Product

Table 89. Genentech, Inc. Recent Developments/Updates

Table 90. Verseon Corp Company Information

Table 91. Verseon Corp Description and Business Overview

Table 92. Verseon Corp Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Verseon Corp Pulmonary Embolism Drug Product

Table 94. Verseon Corp Recent Developments/Updates

Table 95. Key Raw Materials Lists

Table 96. Raw Materials Key Suppliers Lists

Table 97. Pulmonary Embolism Drug Distributors List

Table 98. Pulmonary Embolism Drug Customers List

Table 99. Pulmonary Embolism Drug Market Trends

Table 100. Pulmonary Embolism Drug Market Drivers

Table 101. Pulmonary Embolism Drug Market Challenges

Table 102. Pulmonary Embolism Drug Market Restraints

Table 103. Research Programs/Design for This Report

Table 104. Key Data Information from Secondary Sources

Table 105. Key Data Information from Primary Sources

Table 106. Authors List of This Report

List of Figures

Figure 1. Product Picture of Pulmonary Embolism Drug

Figure 2. Global Pulmonary Embolism Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Pulmonary Embolism Drug Market Share by Type: 2024 & 2031

Figure 4. DS-9231 Product Picture

Figure 5. DS-1040 Product Picture

Figure 6. TRX-1 Product Picture

Figure 7. Others Product Picture

Figure 8. Global Pulmonary Embolism Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Pulmonary Embolism Drug Market Share by Application: 2024 & 2031

Figure 10. Hospital

Figure 11. Clinic

Figure 12. Others

Figure 13. Global Pulmonary Embolism Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Pulmonary Embolism Drug Market Size (2020-2031) & (US$ Million)

Figure 15. Global Pulmonary Embolism Drug Sales (2020-2031) & (K Pcs)

Figure 16. Global Pulmonary Embolism Drug Average Price (USD/Pcs) & (2020-2031)

Figure 17. Pulmonary Embolism Drug Report Years Considered

Figure 18. Pulmonary Embolism Drug Sales Share by Manufacturers in 2024

Figure 19. Global Pulmonary Embolism Drug Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest Pulmonary Embolism Drug Players: Market Share by Revenue in Pulmonary Embolism Drug in 2024

Figure 21. Pulmonary Embolism Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global Pulmonary Embolism Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America Pulmonary Embolism Drug Sales Market Share by Country (2020-2031)

Figure 24. North America Pulmonary Embolism Drug Revenue Market Share by Country (2020-2031)

Figure 25. U.S. Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe Pulmonary Embolism Drug Sales Market Share by Country (2020-2031)

Figure 28. Europe Pulmonary Embolism Drug Revenue Market Share by Country (2020-2031)

Figure 29. Germany Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific Pulmonary Embolism Drug Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific Pulmonary Embolism Drug Revenue Market Share by Region (2020-2031)

Figure 36. China Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Taiwan Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Indonesia Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Thailand Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Malaysia Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Philippines Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Latin America Pulmonary Embolism Drug Sales Market Share by Country (2020-2031)

Figure 47. Latin America Pulmonary Embolism Drug Revenue Market Share by Country (2020-2031)

Figure 48. Mexico Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Brazil Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Argentina Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Middle East and Africa Pulmonary Embolism Drug Sales Market Share by Country (2020-2031)

Figure 52. Middle East and Africa Pulmonary Embolism Drug Revenue Market Share by Country (2020-2031)

Figure 53. Turkey Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Saudi Arabia Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. U.A.E Pulmonary Embolism Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Global Sales Market Share of Pulmonary Embolism Drug by Type (2020-2031)

Figure 57. Global Revenue Market Share of Pulmonary Embolism Drug by Type (2020-2031)

Figure 58. Global Pulmonary Embolism Drug Price (USD/Pcs) by Type (2020-2031)

Figure 59. Global Sales Market Share of Pulmonary Embolism Drug by Application (2020-2031)

Figure 60. Global Revenue Market Share of Pulmonary Embolism Drug by Application (2020-2031)

Figure 61. Global Pulmonary Embolism Drug Price (USD/Pcs) by Application (2020-2031)

Figure 62. Pulmonary Embolism Drug Value Chain

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Pulmonary Hypertension Drug Market Research Report 2025

Global Thrombolytic Treatment Market Research Report 2024

Pulmonary Drug Delivery Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Anticoagulant Medicine Market Research Report 2025

Global Arterial Thrombosis Drug Market Research Report 2024

Global Emphysema Drug Market Research Report 2025

Radioembolization Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Radioembolization Cancer Treatment Market Research Report 2025

Global Heparin Drugs Market Research Report 2024

Idiopathic Pulmonary Fibrosis Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Deep Vein Thrombosis DVT Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Inhaled Anti Infectives Market Research Report 2025

Global Diagnostic Guidewire Market Research Report 2024

Global Pulmonary Arterial Hypertension PAH Drugs Market Research Report 2025

Global Sepsis Diagnostic Market Research Report 2024

Global Cardiovascular Disease Nursing Drugs Market Research Report 2025

Global Pharmerging Market Research Report 2025

Global Proton Pump Inhibitor Drug Market Research Report 2025

Global Diagnostic Sampling Tube Market Research Report 2025

RELATED REPORTS

Global Adult Artificial Heart Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32W16534

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Cardioplegia Adapter Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-33A16598

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Inotropic Drug Injection Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-23Y16200

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Retrograde Cardioplegia Cannula Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29Z16493

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions